《藍籌業績》中生製藥(01177.HK)全年純利27.71億人幣升0.3% 末期息2港仙
中國生物製藥(01177.HK)公布截至去年12月底止全年業績,營業額236.47億元人民幣(下同),按年跌2.4%。純利27.71億元,按年升0.3%;每股盈利14.74分。派末期息2港仙,連同已派發首三個季每季2港仙,全年合共派發股息8港仙。
期內,基本盈利約31.14億元,按年輕微下降約0.3%;稅前盈利為50.13億元,下跌11.9%。研發總開支約28.53億元,佔集團收入約12.1%。
於去年,新產品銷售佔集團總收入約38.1%,達90.1億元,按年上升約79.3%;抗腫瘤用藥銷售額約76.18億元,按年上升約40.3%。
集團指,藥品集中帶量採購和範圍不斷擴大成為國內醫藥行業新常態,競爭激烈的仿製藥利潤空間也會因此受到顯著影響,產業格局調整加快。集中採購降價後的低利潤,以及醫藥代表備案管理後成本不斷提高,難以繼續支撐傳統的處方藥醫院營銷推廣模式。基於網絡平台的營銷和服務模式在未來的醫藥營銷中佔據更重要地位,集團關注到這一趨勢並已著手佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.